Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. Karyopharm is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

Employee Rating

4More
TypeSubsidiary
Parent CompanyBiogen
HQNewton, MA, US
Founded2008
Websitekaryopharm.com
Cybersecurity ratingBMore
Karyopharm Therapeutics was founded in 2008 and is headquartered in Newton, MA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Karyopharm Therapeutics

Sharon Shacham

Sharon Shacham

President and Chief Scientific Officer, Founder
Garen Bohlin

Garen Bohlin

Director
Brian Austad

Brian Austad

Senior Vice President, Pharmaceutical Sciences
Mikael Dolsten

Mikael Dolsten

Director
Tina Beamon

Tina Beamon

Vice President, Chief Compliance Officer
Yosef Landesman

Yosef Landesman

Senior Vice President, Research and Translational Medicine
Show more

Karyopharm Therapeutics Office Locations

Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo
Newton, MA, US (HQ)
85 Wells Ave
München, DE
9 Franziska-Bilek-Weg
Tel Aviv-Yafo, IL
Alon Towers 1, 94 6789155, Yigal Alon St
Show all (3)

Karyopharm Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2008

Total Funding

$248.7 m

Investors

Karyopharm Therapeutics is a subsidiary of Biogen

Karyopharm Therapeutics Revenue

Karyopharm Therapeutics's revenue was reported to be $40.89 m in FY, 2019
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

387.0k229.0k250.0k154.0k30.3m40.9m

Revenue growth, %

(41%)9%

General and administrative expense

5.9m15.9m21.6m23.9m24.9m48.8m105.4m

R&D expense

28.5m60.1m97.7m86.9m107.3m161.4m122.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

171.0k21.0k21.0k150.0k75.0k59.0k48.0k68.0k19.9m239.0k155.0k9.5m13.1m18.1m33.5m21.3m

Cost of goods sold

1.0m

Gross profit

12.1m

Gross profit Margin, %

92%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

156.0m150.6m58.4m49.7m69.0m118.0m128.9m

Accounts Receivable

7.9m

Prepaid Expenses

2.0m2.0m2.0m1.8m6.4m7.3m

Inventories

2.1m346.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

52.9m144.9m132.3m227.1m51.5m24.2m43.5m42.2m37.7m43.9m25.6m55.4m54.5m37.5m119.0m101.6m83.5m75.5m168.0m202.2m103.1m82.3m

Accounts Receivable

7.9m9.3m9.6m

Prepaid Expenses

658.0k2.7m3.0m4.2m2.9m4.1m3.1m1.7m1.5m3.4m2.1m2.1m2.1m2.4m3.4m4.8m7.0m5.7m5.3m7.6m8.0m8.2m

Inventories

100.0k970.0k1.7m2.0m
USDQ3, 2013

Financial Leverage

-1.2 x
Show all financial metrics

Karyopharm Therapeutics Operating Metrics

FY, 2015

Patents Issued

10
Show all operating metrics

Karyopharm Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Karyopharm Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Karyopharm Therapeutics Online and Social Media Presence

Embed Graph

Karyopharm Therapeutics News and Updates

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

SHANGHAI and HONG KONG, Dec. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc....

KARYOPHARM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

New York, NY - (NewMediaWire) - September 20, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) of the September 23, 2019 deadline to seek the role of lead plaintiff in a fede…

Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc.

NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Curaleaf Holdings, Inc. (CURLF) Lifshitz & Miller announces investigation into possible securities laws violation in connection with the FDA's warning letter to Curaleaf stating that several of CURLF's CBD products were "misbranded drugs" in...

ROSEN, A HIGHLY RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - KPTI

NEW YORK, Aug. 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) from March 2, 2017 through February 22, 2019, inclusive (the...

KARYOPHARM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI

NEW ORLEANS, July 26, 2019 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2019 to file lead plaintiff applications in a securities class action lawsuit against...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

NEW YORK, NY - (NewMediaWire) - July 25, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) ("Karyopharm" or the "Company") of the September 23, 2019 deadline to seek the role of lead plaintiff in a federal s…
Show more

Karyopharm Therapeutics Blogs

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update

-- Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020 --

Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

-- Oral XPOVIO Now Available as a Treatment Option for Patients with Multiple Myeloma As Early as First Relapse; Significantly Expands Addressable Patient Population --

Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting

-- In a Randomized Investigator Sponsored Study, XPOVIO in Combination with Standard Induction and Consolidation Chemotherapy Demonstrated Improved Survival in Older, Fit Patients with Acute Myeloid Leukemia -

Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting

-- Pomalyst®, Kyprolis® and Revlimid® Arms of the Phase 1b/2 STOMP Study Evaluating Once Weekly XPOVIO with Low-Dose Dexamethasone Combinations Continue to Demonstrate Favorable Response Rates and Durability in Patients with Previously Treated Multiple Myeloma --
Show more

Karyopharm Therapeutics Frequently Asked Questions

  • When was Karyopharm Therapeutics founded?

    Karyopharm Therapeutics was founded in 2008.

  • Who are Karyopharm Therapeutics key executives?

    Karyopharm Therapeutics's key executives are Sharon Shacham, Garen Bohlin and Brian Austad.

  • How many employees does Karyopharm Therapeutics have?

    Karyopharm Therapeutics has 437 employees.

  • What is Karyopharm Therapeutics revenue?

    Latest Karyopharm Therapeutics annual revenue is $40.9 m.

  • What is Karyopharm Therapeutics revenue per employee?

    Latest Karyopharm Therapeutics revenue per employee is $93.6 k.

  • Who are Karyopharm Therapeutics competitors?

    Competitors of Karyopharm Therapeutics include CytomX Therapeutics, Calithera Biosciences and AVEO Pharmaceuticals.

  • Where is Karyopharm Therapeutics headquarters?

    Karyopharm Therapeutics headquarters is located at 85 Wells Ave, Newton.

  • Where are Karyopharm Therapeutics offices?

    Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo.

  • How many offices does Karyopharm Therapeutics have?

    Karyopharm Therapeutics has 3 offices.